These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

50 related articles for article (PubMed ID: 97122)

  • 21. Effects of indomethacin on viral replication markers in asymptomatic carriers of hepatitis B: a randomized, placebo-controlled trial.
    Bahrami H; Daryani NE; Haghpanah B; Moayyeri A; Moghadam KF; Mirmomen S; Kamangar F
    Am J Gastroenterol; 2005 Apr; 100(4):856-61. PubMed ID: 15784032
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hepatitis B virus reactivation after fludarabine-based regimens for indolent non-Hodgkin's lymphomas: high prevalence of acquired viral genomic mutations.
    Picardi M; Pane F; Quintarelli C; De Renzo A; Del Giudice A; De Divitiis B; Persico M; Ciancia R; Salvatore F; Rotoli B
    Haematologica; 2003 Nov; 88(11):1296-303. PubMed ID: 14607759
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hepatitis B virus DNA in chronic HBsAg carriers: correlation with HBeAg/anti-HBe status, anti-HD and liver histology.
    Stroffolini T; Sagnelli E; Rapicetta M; Felaco FM; Filippini P; Annella T; Petruzziello A; Chionne P; Sarrecchia B; Piccinino F
    Hepatogastroenterology; 1992 Feb; 39(1):62-5. PubMed ID: 1568710
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hepatitis B virus antigen quantitation by radioimmunoassay (RIA) in viral hepatitis and in chronic liver diseases.
    De Ritis F; Gravina E; Squame G
    Acta Hepatogastroenterol (Stuttg); 1975 Feb; 22(1):4-13. PubMed ID: 804225
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antiviral effects of virazole in chronic hepatitis B surface antigen-seropositive chimpanzees.
    Denes AE; Ebert JW; Berquist KR; Murphy BL; Maynard JE
    Antimicrob Agents Chemother; 1976 Sep; 10(3):571-2. PubMed ID: 984798
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of ribavirin in the treatment of acute hepatitis.
    Patki SA; Gupta P
    Chemotherapy; 1982; 28(4):298-303. PubMed ID: 6749447
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Antiviral activity of ribamidyl in experimental infections with California encephalitis group viruses].
    Berezina LK; Bystrova EA; Shliankevich AM; Abramova LN; Gushchina EA; Korbukh IA; Nekrasova EB
    Vopr Virusol; 1989; 34(4):454-8. PubMed ID: 2686163
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [The efficacy of caleflone in treating patients with viral hepatitis].
    Neĭko EM; Pryshliak OIa; Dykyĭ BM
    Lik Sprava; 1995; (9-12):138-9. PubMed ID: 8983756
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lack of specific effect of adenine arabinoside, human interferon, and ribavirin on in vitro production of hepatitis B surface antigen.
    Lemon SM; Bancroft WH
    J Infect Dis; 1979 Nov; 140(5):798-801. PubMed ID: 528792
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Influence of twenty potentially antiviral substances on in vitro multiplication of hepatitis A virus.
    Widell A; Hansson BG; Oberg B; Nordenfelt E
    Antiviral Res; 1986 Mar; 6(2):103-12. PubMed ID: 3010855
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ribavirin: an antiviral agent.
    Sidwell RW; Robins RK; Hillyard IW
    Pharmacol Ther; 1979; 6(1):123-46. PubMed ID: 390559
    [No Abstract]   [Full Text] [Related]  

  • 32. [Antiinfluenza virus activity of virazole by means of quantitative hemadsorption technique (author's transl)].
    Shinkai K; Nishimura T
    Uirusu; 1974 Aug; 24(2):175-80. PubMed ID: 4478988
    [No Abstract]   [Full Text] [Related]  

  • 33. [Mathematical method of evaluation of the effectiveness of treatment of viral hepatitis].
    Zubikova II; Pogozhev IB; Uchaĭkin VF; Sizykh NN; Cherednichenko TV; Moleva TP
    Pediatriia; 1982 Oct; (10):46-9. PubMed ID: 7177747
    [No Abstract]   [Full Text] [Related]  

  • 34. Viral hepatitis in children.
    Kelly D
    Adv Exp Med Biol; 2004; 549():83-90. PubMed ID: 15250519
    [No Abstract]   [Full Text] [Related]  

  • 35. The efficacy of a peptide-nucleic acid solution (Reticulose) for the treatment of hepatitis A and hepatitis B--a preliminary controlled human clinical trial.
    Cohen M
    J R Soc Health; 1992 Dec; 112(6):266-70. PubMed ID: 1469671
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunosuppressive therapy and virus-cores in HBAg-positive chronic hepatitis.
    Kendrey G; Szalka A; László B; Binder L; Hollós I
    Klin Wochenschr; 1975 Nov; 53(22):1081-2. PubMed ID: 1233022
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Update on Hepatitis A Management-Reply.
    Desai AN; Kim AY
    JAMA; 2021 Jan; 325(4):401-402. PubMed ID: 33496769
    [No Abstract]   [Full Text] [Related]  

  • 38. [Action of an anti-viral on the Australia antigen in patients with hepatitis A virus and in healthy carriers].
    Vilela MD; Siqueira WA; Rodriguez LD; Domingues SH; Rodrigues FD
    G E N; 1977; 31(3):149-55. PubMed ID: 97122
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Action of 1-beta-D-ribofuranosyl, 1,2,4-triazol-3-carboxamide on the treatment of acute viral hepatitis].
    Zuñiga CB; de Almeida C; Iervolino AC; Castro Ide O; Galvão PA
    AMB Rev Assoc Med Bras; 1974 Nov; 20(11):386-90. PubMed ID: 4615344
    [No Abstract]   [Full Text] [Related]  

  • 40. Response to interferon-alpha in chronic hepatitis B patients with and without precore mutant strain and effects on HBsAg titers.
    Akhan SC; Yulugkural Z; Vahaboglu H
    Chemotherapy; 2007; 53(6):402-6. PubMed ID: 17934260
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.